Corcept Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Corcept Therapeutics reports strong 2025 revenue growth driven by Korlym sales, despite an FDA Complete Response Letter for relacorilant in hypercortisolism, while oncology programs show promising advancements.
NASDAQ
Corcept Therapeutics achieved record revenue in 2024 and submitted a New Drug Application (NDA) to the FDA for relacorilant, a potential treatment for hypercortisolism.
NASDAQ
Corcept Therapeutics' 2023 10-K filing reveals increased revenue, ongoing clinical trials, and legal challenges.